Efficacy and Safety of Fig (Ficus carica L.) Leaf Tea in Adults with Mild Atopic Dermatitis: A Double-Blind, Randomized, Placebo-Controlled Preliminary Trial

被引:10
|
作者
Abe, Tatsuya [1 ]
Koyama, Yukari [1 ]
Nishimura, Kosaku [1 ]
Okiura, Aya [1 ]
Takahashi, Toru [1 ]
机构
[1] Toyo Inst Food Technol, 23-2,4 Chome, Kawanishi, Hyogo 6660026, Japan
关键词
atopic dermatitis; Eczema Area and Severity Index (EASI); RCT; functional food; Ficus carica; ACTIVATION-REGULATED CHEMOKINE; HEPATOPROTECTIVE ACTIVITY; EXTRACT; ECZEMA; PROBIOTICS; DISEASE; THYMUS; PREVENTION; OMALIZUMAB; PREGNANCY;
D O I
10.3390/nu14214470
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Atopic dermatitis (AD) is a chronic, recurrent pruritic skin disease with repeated remissions and exacerbations. Various factors, such as allergies, skin conditions and lifestyle, combine to cause AD, making it difficult to cure completely. Although AD symptoms are suppressed with medications, this is a long-term effort and burden on patients. Thus, safer drugs and alternatives are needed. We previously found that consumption of tea prepared from fig (Ficus carica L.) leaves alleviated allergy and AD symptoms in cultured cells and animals. Therefore, here, we conducted a double-blind, randomized, controlled study in patients with mild AD to evaluate the safety and AD-relieving effects of prolonged consumption of fig leaf tea. Positive effects of fig leaf tea consumption were confirmed in 14 of 15 participants. Eczema Area and Severity Index values were significantly lowered in the fig leaf tea-treated group than in the placebo-treated group. The effect weakened 4 weeks after the end of the intervention, suggesting that continued intake of fig leaf tea was effective. Further assessments confirmed the safety of fig leaf tea consumption and revealed no variations that might pose a health hazard. Therefore, we postulate that fig leaf tea is a natural and safe therapeutic option for AD.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Efficacy and safety of Kami-guibi-tang for mild cognitive impairment: a pilot, randomized, double-blind, placebo-controlled trial
    Shin, Hee-Yeon
    Kim, Ha-Ri
    Jahng, Geon-Ho
    Jin, Chul
    Kwon, Seungwon
    Cho, Seung-Yeon
    Park, Seong-Uk
    Jung, Woo-Sang
    Moon, Sang-Kwan
    Ko, Chang-Nam
    Park, Jung-Mi
    BMC COMPLEMENTARY MEDICINE AND THERAPIES, 2021, 21 (01)
  • [32] The efficacy and safety of nimodipine in acute ischemic stroke patients with mild cognitive impairment: a double-blind, randomized,placebo-controlled trial
    Huaguang Zheng
    Yilong Wang
    Anxin Wang
    Hao Li
    David Wang
    Xingquan Zhao
    Penglian Wang
    Haipeng Shen
    Lijun Zuo
    Yuesong Pan
    Zixiao Li
    Xia Meng
    Xianwei Wang
    Weixiong Shi
    Yi Ju
    Liping Liu
    Kehui Dong
    Chunxue Wang
    Rubo Sui
    Rong Xue
    Xiaoping Pan
    Xiaoyua Niu
    Benyan Luo
    Yi Sui
    Huali Wang
    Tao Feng
    Yongjun Wang
    Science Bulletin, 2019, 64 (02) : 101 - 107
  • [33] Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial
    Viljanen, M
    Savilahti, E
    Haahtela, T
    Juntunen-Backman, K
    Korpela, R
    Poussa, T
    Tuure, T
    Kuitunen, M
    ALLERGY, 2005, 60 (04) : 494 - 500
  • [34] A randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of a Chinese herbal product (P07P) for the treatment of canine atopic dermatitis
    Nagle, TM
    Torres, SM
    Horne, KL
    Grover, R
    Stevens, MT
    VETERINARY DERMATOLOGY, 2001, 12 (05) : 265 - 274
  • [35] Evaluation of efficacy and safety of Lactobacillus rhamnosus in children aged 4-48 months with atopic dermatitis: An 8-week, double-blind, randomized, placebo-controlled study
    Wu, Yi-Jie
    Wu, Wei-Fong
    Hung, Chia-Wei
    Ku, Ming-Shiu
    Liao, Pei-Fen
    Sun, Hai-Lun
    Lu, Ko-Hsiu
    Sheu, Ji-Nan
    Lue, Ko-Huang
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2017, 50 (05) : 684 - 692
  • [36] Efficacy and safety of lebrikizumab combined with topical corticosteroids in Japanese patients with moderate-to-severe atopic dermatitis: a phase 3, double-blind, placebo-controlled, randomized clinical trial (ADhere-J)
    Katoh, Norito
    Tanaka, Akio
    Takahashi, Hidetoshi
    Shimizu, Ryosuke
    Kataoka, Yoko
    Torisu-Itakura, Hitoe
    Morisaki, Yoji
    Igawa, Ken
    CURRENT MEDICAL RESEARCH AND OPINION, 2025, 41 (01) : 1 - 12
  • [37] Efficacy and safety of pentavalent rotavirus vaccine in Japan A randomized, double-blind, placebo-controlled, multicenter trial
    Iwata, Satoshi
    Nakata, Shuji
    Ukae, Susumu
    Koizumi, Yoshitugu
    Morita, Yasuyuki
    Kuroki, Haruo
    Tanaka, Yoshiyuki
    Shizuya, Toshiyuki
    Schoedel, Florian
    Brown, Michelle L.
    Lawrence, Jody
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2013, 9 (08) : 1626 - 1633
  • [38] Efficacy and tolerability of a Chinese herbal medicine concoction for treatment of atopic dermatitis: a randomized, double-blind, placebo-controlled study
    Hon, K. L. E.
    Leung, T. F.
    Ng, P. C.
    Lam, M. C. A.
    Kam, W. Y. C.
    Wong, K. Y.
    Lee, K. C. K.
    Sung, Y. T.
    Cheng, K. F.
    Fok, T. F.
    Fung, K. P.
    Leung, P. C.
    BRITISH JOURNAL OF DERMATOLOGY, 2007, 157 (02) : 357 - 363
  • [39] Efficacy and safety of retapamulin ointment as treatment of impetigo: randomized double-blind multicentre placebo-controlled trial
    Koning, S.
    Van der Wouden, J. C.
    Chosidow, O.
    Twynholm, M.
    Singh, K. P.
    Scangarella, N.
    Oranje, A. P.
    BRITISH JOURNAL OF DERMATOLOGY, 2008, 158 (05) : 1077 - 1082
  • [40] Efficacy of a Cream Containing Ceramides and Magnesium in the Treatment of Mild to Moderate Atopic Dermatitis: A Randomized, Double-blind, Emollient- and Hydrocortisone-controlled Trial
    Koppes, Sjors A.
    Charles, Frank
    Lammers, Laureen A.
    Frings-Dresen, Monique
    Kezic, Sanja
    Rustemeyer, Thomas
    ACTA DERMATO-VENEREOLOGICA, 2016, 96 (07) : 948 - 953